External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
JAMA Netw Open. 2022;5(1):e2144170. doi:10.1001/jamanetworkopen.2021.44170 - January 19, 2022
How does a previously prospectively derived clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy perform prognostically in an external validation cohort?
Read full article>>
Other news & events
- News01.07.2026

Türkiye Introduces Reimbursement for Actinium-225 PSMA Therapy
Read more - News12.05.2026

#ASCO26 - Radiopharmaceutical Therapy in Oncology: Practical Integration for Practicing Oncologists
Read more - News11.05.2026

Oncidium foundation partners with Curium to expand access to Radioligand Therapy worldwide
Read more




